Read more
Retinoic Acids in Cancer Therapy: Mechanisms of Sensitivity, Resistance, and Methods of Delivery provides a comprehensive overview on how ATRA (All Trans Retinoic Acid) kills cancer cells and how some cells survive when they are treated with this drug. With a strong focus on cell pathways and compartments involved in the action of RAs in inhibiting cell proliferation in various cancers, coverage includes how aggressive tumors develop as well as several escape routes conferring RAs-resistance.
In 16 chapters the book describes the molecular structure and biological properties of ATRA, explains the mechanisms of resistance to ATRA, defines the efficiency of trans-retinoic acid on 7 various cancers, shows strategies to improve ATRA cancer treatment and provides future perspectives in ATRA applications. This book is a valuable reference for health professionals, scientists, researchers, health practitioners, students, and all those who wish to broaden their knowledge in the field to develop new drugs or treatment strategies that improve the therapeutic efficacy of ATRA in cancers.
List of contents
1. Molecular structure and biological properties of ATRA
2. Cellular and molecular determinants of all-trans retinoic acid sensitivity in different cancers
3. Mechanisms of resistance to ATRA
4. Efficiency of All-Trans Retinoic Acid on Gastric Cancer
5. Efficiency of All-Trans Retinoic Acid on glioblastoma
6. Efficiency of All-Trans Retinoic Acid on lung cancer
7. Efficiency of All-Trans Retinoic Acid on breast cancer
8. Efficiency of All-Trans Retinoic Acid on liver cancer
9. Efficiency of All-Trans Retinoic Acid on stomach cancer
10. Efficiency of All-Trans Retinoic Acid on colon cancer
11. Bioengineered models for investigating ATRA anticancer efficacy and biocompatibility
12. Delivery methods for ATRA
13. Apoptosis, autophagy, and UPR and its impact in ATRA-induced toxicity in cancer cells.
14. ATRA and Cancer Stem Cell Biology
15. OMICs strategies to Improve the ATRA Cancer Treatment
16. Future Perspectives in ATRA applications in Cancer Biology and Nano technology
About the author
Dr. Ghavami completed his undergraduate training MSc and PhD in clinical biochemistry. He is a cancer biologist and his research focusses on the importance of cross talk of three key cellular stress [apoptosis, autophagy and unfolded protein response (UPR)] in regulation of chemotherapy response in cancer cells including Glioblastoma, Rhabdomyosarcoma and non-small cell lung adenocarcinoma. Dr. Ghavami is currently honorary professor and co-founder of Autophagy Research Centre at Shiraz University of Medical Science and Tehran University of Medical Sciences, honorary professor at Katowice School of Technology, Poland. He is associate editor of BBA-Mol Basis of Disease, Molecular Neurobiology, BB Reports and IJMS.Ali Zarrabi is an Associate Professor and Principal Investigator in the Faculty of Engineering and Natural Sciences, at Istinye University, in Turkey. He holds a bachelor's degree in Chemical Engineering from Isfahan University of Technology, a master's degree in Chemical Engineering from Sharif University of Technology, and a PhD in Nanobiotechnology from Sharif University of Technology. His group works at the interface of supramolecular chemistry, bioengineering, and medicine to develop approaches for simultaneous diagnosis and treatment of diseases. He has been active as a faculty member for more than 12 years. His current research interests include nanomaterials, nanotheranostics, novel wound dressing and skin patches, and translational nanomedicine. Developing wearable biosensors and diagnostic patches has recently been considered in Zarrabi Lab.Marco Cordani obtained his Ph.D. at the University of Verona, working on the implication of mutated p53 proteins in metabolism and autophagy. Later, he has performed two postdoctoral stays, one at Universidad Autónoma de Madrid (2017) and another at the IMDEA Nanociencia (2018-2020), working on novel nanomedicine and gene editing strategies to counteract cancer. Currently, Postdoctoral Researcher at the University “Claude Bernard” Lyon 1, characterizing the involvement of dependence receptors in cell death and metabolism.
